The XV Congress of the European Society of retina specialists («EURETINA - 2015")


The XV Congress of the European Society of retina specialists («EURETINA - 2015") took place in Nice (France) from 17 – 20 September, 2015. The venue of the event was Nice Acropolis Congress Centre - the largest exhibition center of Nice.

The congress was attended by more than four thousand experts and researchers in the field of pathology of the retina and vitreous from the 53 countries. The scientific program of the congress included 11 main sessions, 20 training courses, 19 sessions of oral reports and 20 satellite symposia. The meetings were held simultaneously in 6 halls. The main directions of the Congress:

· Age-related macular degeneration
· Surgery of the anterior and posterior segments of the eye
· Intraocular neoplasms
· New technologyin retinal pathology therapy
· Uveitis
· Diabetic eye disease
· Vitreoretinal surgery 


At the opening ceremony Prof. Francesco Bandello, EURETINA President, said that the annual congress of vitreoretinal surgery provides the main impetus for the research and development of vitreoretinal surgery. A lecture of the courses on vitreoretinal surgery of Prof. I.Kreissig was presented during the opening ceremony of the Congress, all her awards were listed and special attention was given the title of honorary professor of Ufa Eye Research Institute.

The main sessions were devoted to the problems of diagnosis and treatment of ophthalmopathology: intraocular tumors, neovascularization in age-related macular degeneration, inflammatory diseases of the eye, wet macular degeneration, retinal venous occlusive disease, PVR and rhegmatogenous retinal detachment, diabetic retinopathy. The mapping of pathological changes of the fundus and innovative technologies of vitreoretinal surgery were considered.

Only 5 oral reports from Russia were included in the scientific program. It is important to note that 3 of them were represented by doctors of Ufa Eye Research Institute. In addition, some reports were accepted to participate in the poster session. Thus, Ufa Eye Research Institute presented 8 reports on major developments in vitreoretinal surgery: 

  • FP-7631 - Central retina mapping in diabetic macular edema when perfoming antivasoproliferative therapy (M.M. Bikbov, T.R. Gilmanshin, R.R. Fayzrakhmanov, R.M. Zainullin)
  • FP-7635 - Intravitreal insertion of dexamethasone implant in treatment of consequences of retinal vein thrombosis (M.M. Bikbov, T.R. Gilmanshin, R.R. Fayzrakhmanov, I.I. Gilyazova)
  • FP-7175 - Cytokine profile of aqueous humour of anterior chamber in patients with age-related macular degeneration (M.M. Bikbov, N.E. Shevchuk, R.R. Fayzrakhmanov)
  • FP-7176 - Antivazoproliferative therapy efficacy in patients with age-related macular degeneration in the long-term follow-up period at different levels of localization of choroidal neovascularization (M.M. Bikbov, R.R. Fayzrakhmanov)
  • POS-7178 - Angiogenesis blockade effect on fibrovascular membrane development in patients with age-related macular degeneration (M.M. Bikbov, R.R. Fayzrakhmanov)
  • POS-7180 - A new technique of surgical treatment of patients with high detachment of retinal pigment epithelium in age-related macular degeneration (M.M. Bikbov, R.R. Fayzrakhmanov)
  • POS-7638 - Characteristics of central retina in patients with diabetic macular edema (M.M. Bikbov, T.R. Gilmanshin, R.R. Fayzrakhmanov, R.M. Zainullin, M.R. Kalanov).
  • Baseline characteristics of patients with neovascular age-related macular degeneration from the cohort of Russian patients in the observational LUMINOUS STUDY (M.M. Bikbov).

Cytokine profile of aqueous humour of anterior chamber in patients with age-related macular degeneration - oral report was presented by Dr. R. Fayzrahmanov and aroused great interest and discussion that underlines the fundamental aspects presented in the report.

This year all ophthalmological societies from all continents - Europe, America, Asia and Africa were presented on the Congress. To this end, World Retina Night was organized, where representatives of each area could discuss problems of ophthalmology; and identify ways of their solving.

Great interest among the participants of the congress was generated by video session, which presented new methods of surgical treatment. Poster session included more than 70 presentations.

The exhibition was attended by 68 companies, which presented new developments in the treatment of retinal diseases. The works in the treatment of macular pathology deserve particular attention. Sylmar (California, USA) manufactures a device "Second Sight", which is a retinal prosthesis for patients with advanced retinitis pigmentosa - a degenerative eye disease that can lead to blindness. This is the first approved prosthesis to treat the disease in the United States. Intraretinal chip Argus II was created on its basis. This implant provides object vision that is very valuable for blind person.

Company Alcon, Opticon presented new equipment for vitreoretinal surgery - Vitreoretinal machines such as Constilation, Revolution, providing to conduct operations with a high rate cuts.



Back to the list